Literature DB >> 20148978

Mortality and causes of death in Italian persons with haemophilia, 1990-2007.

A Tagliaferri1, G F Rivolta, A Iorio, E Oliovecchio, M E Mancuso, M Morfini, A Rocino, M G Mazzucconi, M Franchini, N Ciavarella, A Scaraggi, L Valdrè, G Tagariello, P Radossi, G Muleo, P G Iannaccaro, C Biasoli, D Vincenzi, M L Serino, S Linari, C Molinari, E Boeri, M La Pecorella, M T Carloni, E Santagostino, G Di Minno, A Coppola, A Rocino, E Zanon, L Spiezia, C Di Perna, M Marchesini, M Marcucci, A Dragani, S Macchi, P Albertini, M D'Incà, C Santoro, F Biondo, G Piseddu, G Rossetti, G Barillari, G Gandini, A C Giuffrida, G Castaman.   

Abstract

Although a number of studies have analysed so far the causes of death and the life expectancy in haemophilic populations, no investigations have been conducted among Italian haemophilia centres. Thus, the aim of this study was to investigate mortality, causes of deaths, life expectancy and co-morbidities in Italian persons with haemophilia (PWH). Data pertaining to a total of 443 PWH who died between 1980 and 2007 were retrospectively collected in the 30 centres who are members of the Italian Association of Haemophilia Centres that chose to participate. The mortality rate ratio standardized to the male Italian population (SMR) was reduced during the periods 1990-1999 and 2000-2007 such that during the latter, death rate overlapped that of the general population (SMR 1990-1999: 1.98 95% CI 1.54-2.51; SMR 2000-2007: 1.08 95% CI 0.83-1.40). Similarly, life expectancy in the whole haemophilic population increased in the same period (71.2 years in 2000-2007 vs. 64.0 in 1990-1999), approaching that of the general male population. While human immunodeficiency virus infection was the main cause of death (45%), 13% of deaths were caused by hepatitis C-associated complications. The results of this retrospective study show that in Italian PWH improvements in the quality of treatment and global medical care provided by specialized haemophilia centres resulted in a significantly increased life expectancy.

Entities:  

Mesh:

Year:  2010        PMID: 20148978     DOI: 10.1111/j.1365-2516.2009.02188.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  46 in total

1.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

2.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

3.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 4.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

7.  Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Authors:  Giovanni Di Minno; Mariana Canaro; James W Ironside; David Navarro; Carlo Federico Perno; Andreas Tiede; Lutz Gürtler
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

Review 8.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

9.  Tailoring care to haemophilia patients' needs: which specialty and when?

Authors:  Massimo Morfini; Gary Benson; Victor Jiménez-Yuste; Rolf Ljung; Pier Mannuccio Mannucci; Gianluigi Pasta; Eduardo Remor; Silva Zupančić Šalek
Journal:  Blood Transfus       Date:  2015-05-20       Impact factor: 3.443

10.  The Incidence Rates and Standardized Incidence Ratios of Cancer in Hemophilic HIV/AIDS Patients in Taiwan.

Authors:  Marcelo Chen; Ian Jen; Gerald B Sharp; Yi-Ming Arthur Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.